Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP809043.RA7o4a5VIx20RVvJCieQsC-4PjRbJP8UtZP8J4sj_YhRY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP809043.RA7o4a5VIx20RVvJCieQsC-4PjRbJP8UtZP8J4sj_YhRY130_assertion type Assertion NP809043.RA7o4a5VIx20RVvJCieQsC-4PjRbJP8UtZP8J4sj_YhRY130_head.
- NP809043.RA7o4a5VIx20RVvJCieQsC-4PjRbJP8UtZP8J4sj_YhRY130_assertion description "[The incidence of TET2, ASXL1, CBL, IDH or IKZF1 mutations in these disorders ranges from 0 to 17%; these latter mutations are more common in chronic (TET2, ASXL1, CBL) or juvenile (CBL) myelomonocytic leukemias, mastocytosis (TET2), myelodysplastic syndromes (TET2, ASXL1) and secondary acute myeloid leukemia, including blast-phase MPN (IDH, ASXL1, IKZF1).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP809043.RA7o4a5VIx20RVvJCieQsC-4PjRbJP8UtZP8J4sj_YhRY130_provenance.
- NP809043.RA7o4a5VIx20RVvJCieQsC-4PjRbJP8UtZP8J4sj_YhRY130_assertion evidence source_evidence_literature NP809043.RA7o4a5VIx20RVvJCieQsC-4PjRbJP8UtZP8J4sj_YhRY130_provenance.
- NP809043.RA7o4a5VIx20RVvJCieQsC-4PjRbJP8UtZP8J4sj_YhRY130_assertion SIO_000772 20428194 NP809043.RA7o4a5VIx20RVvJCieQsC-4PjRbJP8UtZP8J4sj_YhRY130_provenance.
- NP809043.RA7o4a5VIx20RVvJCieQsC-4PjRbJP8UtZP8J4sj_YhRY130_assertion wasDerivedFrom befree-2016 NP809043.RA7o4a5VIx20RVvJCieQsC-4PjRbJP8UtZP8J4sj_YhRY130_provenance.
- NP809043.RA7o4a5VIx20RVvJCieQsC-4PjRbJP8UtZP8J4sj_YhRY130_assertion wasGeneratedBy ECO_0000203 NP809043.RA7o4a5VIx20RVvJCieQsC-4PjRbJP8UtZP8J4sj_YhRY130_provenance.